Anti-angiogenic agents induce hypoxia within the tumour microenvironment which in turn activates the p130/E2F4 complex; by binding to E2F consensus sequences in HR promoter genes, the activated complex thus down-regulates key HR genes such as BRCA1/2 and RAD51 (77). This evidence concerns the gene BRCA1 and neoplasm.